Use of endocrine therapy for estrogen receptor-positive breast cancer among American Indians and Alaska natives Marta EngelkingSchelomo MarmorTodd M. Tuttle Review 23 January 2023 Pages: 187 - 195
Distinct breast cancer phenotypes in BRCA 1/2 carriers based on ER status Shai RosenbergMichal DevirTamar Peretz Preclinical Study 02 February 2023 Pages: 197 - 205
Prognostic significance of pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer who underwent adjuvant chemotherapy Sangwon HanSae Byul LeeDae Hyuk Moon Clinical Trial 12 January 2023 Pages: 207 - 215
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer Christos VaklavasErica M. Stringer-ReasorAndres Forero-Torres Clinical trial Open access 03 February 2023 Pages: 217 - 229
Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer Sung Eun KimWon-Ji KimDong-Yun Lee Clinical trial 13 February 2023 Pages: 231 - 237
Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry Khava I. E. IbragimovaSandra M. E. GeurtsVivianne C. G. Tjan-Heijnen Epidemiology Open access 12 January 2023 Pages: 239 - 251
Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference—a Dutch population-based study from 2008 to 2018 Josanne S. de MaarMarianne LuyendijkElsken van der Wall Epidemiology 17 January 2023 Pages: 253 - 264
International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients K. M. de LigtB. H. de Rooijthe Innovative Medicines Initiative - Health Outcomes Observatory (H2O) consortium Epidemiology Open access 20 January 2023 Pages: 265 - 281
Pregnancy-associated breast cancer: does timing of presentation affect outcome? Angelena CrownDamian McCartanMary L. Gemignani Epidemiology 20 January 2023 Pages: 283 - 294
Immediate or delayed oncoplastic surgery after breast conserving surgery at the Netherlands Cancer Institute: a cohort study of 251 cases Ariane A. van LoevezijnCharissa S. GelukMarije J. Hoornweg Epidemiology 24 January 2023 Pages: 295 - 307
Chemotherapy refusal and subsequent survival in healthy older women with high genomic risk estrogen receptor-positive breast cancer McKenzie J. WhiteMadison KolbowSchelomo Marmor Epidemiology 24 January 2023 Pages: 309 - 319
False-positive incidental lesions detected on contrast-enhanced breast MRI: clinical and imaging features Afsaneh AlikhassiXuan LiVivianne Freitas Epidemiology 06 February 2023 Pages: 321 - 334
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk Richard AllmanYi MuBernard A. Rosner Epidemiology Open access 07 February 2023 Pages: 335 - 347
Contrast-enhanced mammography in the assessment of residual disease after neoadjuvant treatment Molly P. HoganJoao V. HorvatJanice S. Sung Epidemiology 09 February 2023 Pages: 349 - 359
Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk Maria SundHans GarmoAntonis Valachis Epidemiology Open access 11 February 2023 Pages: 361 - 368
Neighborhood and racial influences on triple negative breast cancer: evidence from Northeast Ohio Kirsten Y. EomKristen A. BergKhalid Sossey-Alaoui Epidemiology 13 February 2023 Pages: 369 - 381
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study Mark Jesus M. MagbanuaLaura van ‘t VeerAngela DeMichele Original Laboratory Investigation 23 January 2023 Pages: 383 - 390
Molecular characteristics of Asian male BRCA-related cancers Ava KwongCecilia Yuen Sze HoEdmond Shiu Kwan Ma Letter to the Editor 13 January 2023 Pages: 391 - 400
Mitigating fear of cancer recurrence Steven Sorscher Letter to the Editor 03 February 2023 Pages: 401 - 401
High maximum standardized uptake value might be associated more with T2b (≥ 4 cm) than T2a (< 4 cm) in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer Kadri Altundag Letter to the Editor 03 February 2023 Pages: 403 - 403
